Oppenheimer analyst Hartaj Singh lowered the firm’s price target on Eloxx Pharmaceuticals to $50 from $120 post-reverse split, while keeps an Outperform rating on the shares. The analyst notes Eloxx reported Q3 financial/research updates, and its stock started to trade on a 1-for-40 reverse split basis in December 22.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELOX: